Vitura Health

What Vitura Health does

Vitura Health Limited (ASX: VIT), formerly Cronos Australia, is a vertically integrated Australian digital health company founded in 2016 and headquartered in South Yarra. It builds and operates a connected ecosystem for alternative therapies, centered on the Canview B2B platform that enables registered health professionals to browse, e-prescribe, dispense, and order medicinal cannabis and related medicines in a single TGA-compliant workflow with live stock visibility, auto-matching, and clinical software integration.

The company's commercial model spans four revenue streams: transactional product distribution through the Canview marketplace and the Burleigh Heads Cannabis (BHC) nationwide pharmacy network (covering approximately 4,700 Australian pharmacies), telehealth consultation fees via the owned Doctors on Demand and Candor Medical services (with 120+ doctors on the network), subscription and platform fees for prescriber tooling, and a 50/50 joint venture (Cortexa, with PharmAla Biotech) supplying AU-GMP validated MDMA and psilocybin to Australian clinicians. Its owned brand portfolio includes CDA Clinics, Cannadoc, Adaya, and Inscape for product and clinic operations, with growth driven by a mix of acquisitions (most notably the $25M Doctors on Demand deal in October 2023), distribution partnerships (MedReleaf Australia, March 2026), and brand expansion. The company serves three customer segments — patients seeking alternative therapies, healthcare prescribers, and Australian pharmacies — and is exposed to TGA regulatory risk on the scheduling of cannabis and psychedelic products.

Name

Vitura Health

Legal name

Vitura Health Limited

Website

https://vitura.com.au

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Vitura Health is an ASX-listed Australian digital health company operating a vertically integrated platform for medicinal cannabis and alternative therapies, connecting patients, prescribers, and approximately 4,700 pharmacies through its Canview marketplace, owned telehealth brands, and a psychedelics joint venture.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis Digital Health

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Other Health Practitioners (6213), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Services-Offices & Clinics Of Doctors Of Medicine (8011), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industries

Controlled-Substance & High-Risk Medication Teleprescribing Platforms (compliance-focused) (HLALAIAM), Direct-to-Consumer Telehealth Marketplaces (Multi-Provider Aggregators) (HLALAAAJ), Cannabis Subscription & Membership Delivery Programs (CRANAGAI)

Keywords

• Medicinal cannabis distribution
• Telehealth consultations
• Digital health platform
• Alternative therapy prescribing
• Pharmacy supply network

Headquarters

HQ city

South Yarra

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Telehealth Consultations: Virtual healthcare consultations through Doctors on Demand platform, providing on-demand access to doctors for mental health, smoking cessation, medicated weight loss, and other medications.
2. Product Distribution: Distribution of medicinal cannabis, psychedelics, and alternative therapy products through Canview platform to pharmacies and direct to patients via prescriber orders.
3. Platform/SaaS Fees: Canview platform enables prescribers to generate and manage e-prescriptions, view live stock levels, with TGA approval, storage and auto-matching capabilities.
4. MedReleaf Distribution Revenue: Distribution agreement with MedReleaf Australia estimated to contribute up to $15 million in additional annual revenue through MedReleaf's full suite of medicinal cannabis products on the Canview platform.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Vitura Health operates a vertically integrated digital health ecosystem for alternative therapies in Australia. Its core offering is the Canview online platform that enables registered health professionals to browse, prescribe, and order medicinal cannabis and other alternative therapy medicines, complemented by telehealth services (Doctors on Demand, Candor Medical, Cannadoc), physical clinic networks (CDA Clinics), distribution through Burleigh Heads Cannabis to approximately 4,700 Australian pharmacies, and a 50/50 joint venture (Cortexa) supplying validated psychedelics.

Product overview

Vitura Health operates as a digital health platform with a diversified portfolio of brands spanning telehealth, medicinal cannabis, alternative therapies, and emerging therapeutics. The core platform is Canview, an online prescribing and medication management system for alternative therapies. This is supported by owned and partnered clinic brands (CDA Clinics, Cannadoc, Candor Medical), the telehealth service Doctors on Demand, distribution capabilities through BHC, and product brands (Adaya, Inscape). The company also holds a 50% stake in Cortexa for psychedelics supply. The architecture combines a central digital health ecosystem connecting patients, prescribers, pharmacists, and suppliers through integrated technology, distribution, and educational services.

Differentiator

Problem solved

Functional benefit

Brands

• Canview: Online platform delivering prescribing, dispensing and medication management solutions for alternative therapies
• Doctors on Demand
• Cortexa
• CDA Clinics
• Cannadoc
• BHC
• Adaya
• Candor Medical
• Inscape

Products and services

• Canview An online platform delivering prescribing, dispensing, and medication management solutions for alternative therapies. Enables registered health professionals to browse, prescribe, and order medicines from multiple suppliers in one streamlined, compliant, free-to-use platform, with e-prescription management, live stock level viewing, TGA approval handling, storage and auto-matching, and integration with clinical software.
• Doctors on Demand On-demand telehealth service providing virtual healthcare consultations across Australia, enabling patients to connect with healthcare practitioners for mental health, smoking cessation, medicated weight loss, and other medication-related consultations.
• Cortexa Australian company supplying validated psychedelics (GMP MDMA and psilocybin) ready for patient use, supporting clinicians and clinical research sites throughout Australia. One of only a few companies in the world able to supply validated psychedelics for patient use.
• Candor Medical Doctor-led telehealth provider offering alternative therapy, hair loss, mental health support, and sexual health consultations through an intuitive online booking and appointment management platform.
• CDA Clinics Alternative therapy clinic providing consultations and prescription services to eligible Australian patients, staffed by experienced doctors focused on comprehensive knowledge and compassionate care in the alternative therapy space.
• Cannadoc Alternative therapy clinic offering nation-wide telehealth consultations dedicated to improving quality of life for patients and leading the way in management of complex, chronic conditions.
• Burleigh Heads Cannabis (BHC) One of Australia's largest alternative therapy distributors, partnering with domestic and international suppliers and leveraging a national footprint and logistics partners to supply scheduled medications to thousands of pharmacies and doctors via the Canview platform.
• Adaya Product brand featuring a portfolio of hybrid formulations and Australian-cultivated medicinal cannabis products with emphasis on quality and affordability, manufactured in compliance with AU-GMP pharmaceutical quality and safety standards.
• Inscape Carefully crafted medicinal cannabis formulations designed to support individual needs, with a focus on quality, safety, and personalized care adhering to rigorous standards for consistency and peace of mind.

Quantifiable outcome

• MedReleaf distribution agreement estimated to contribute up to $15 million in additional annual revenue
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• MedReleaf AustraliacoreChannel Partner/ Reseller/ Distributor · 17 March 2026Commercial distribution agreement making MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview platform, distributed through the Burleigh Heads Cannabis nationwide network. MedReleaf is a wholly owned subsidiary of Aurora Cannabis with brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co. Deal estimated to contribute up to $15 million in additional annual revenue.
• PharmAla BiotechcoreStrategic or Co-development Partner · 1 July 202350/50 joint venture between PharmAla Biotech and Vitura Health to form Cortexa. PharmAla produces GMP MDMA and psilocybin for the Australian market, with ongoing royalty provisions. Production of second GMP batch of 20mg MDMA capsules expected Q2 2026. Licensing arrangement concludes during FY2026 with royalty provisions maintained.
• Aurora CannabisminorChannel Partner/ Reseller/ DistributorParent company of MedReleaf Australia, indirectly partnered through MedReleaf distribution agreement. Offers products under brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co.
• Burleigh Heads CannabiscoreChannel Partner/ Reseller/ DistributorDistribution network partner for Canview platform, enabling nationwide distribution of alternative therapy products to pharmacies across Australia.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Incannex Healthcare: ASX-listed clinical-stage cannabinoid and psychedelic pharmaceutical developer. Comparable to Vitura's Cortexa psychedelics JV and chronic-condition therapeutic focus, with overlap on psychedelic clinical development.
• Little Green Pharma: ASX-listed Australian medicinal cannabis producer and distributor with its own clinic network and product portfolio. Direct competitor to Vitura in TGA-licensed cannabis cultivation, distribution, and patient access.
• Zelira Therapeutics: Australia-based cannabinoid and psychedelic therapeutics developer with a focus on clinically validated formulations. Comparable to Vitura's Adaya/Inscape product brands and Cortexa psychedelic supply activity.
• Althea Group Holdings: Australian medicinal cannabis company combining product manufacturing with a pharmacy and patient education platform. Directly comparable to Vitura's vertically integrated cannabis distribution and prescriber-engagement model.
• Emyria (formerly Emerald Clinics): Australian clinical cannabinoid company operating specialty clinics and generating real-world patient data. Directly comparable to Vitura's CDA Clinics and Cannadoc clinic brands and alternative therapy prescribing model.

Broad incumbents

• Canopy Growth: Large global cannabis producer with medical and consumer product lines. Comparable to Vitura's distribution and product brand portfolio at multinational scale; potential future platform partner or competitor in Australian medicinal cannabis.
• Aurora Cannabis: Global licensed cannabis producer and parent of MedReleaf Australia — a current Vitura distribution partner. Larger-scale incumbent providing product to Canview; comparable business model at multinational scale.
• Tilray Brands: Global cannabis and pharmaceutical company with operations across cultivation, distribution, and patient access. Broad incumbent with overlapping Australian distribution interests and end-to-end cannabis value chain comparable to Vitura.

Emerging players

• Eucalyptus: Australian digital health platform operating telehealth clinics across weight management, men's health, and chronic conditions. Comparable to Vitura's Doctors on Demand and Candor Medical telehealth assets in patient acquisition and recurring consult model.
• Mosh (previously Mosh Men's Health): Australian subscription telehealth provider focused on men's and women's health conditions. Comparable to Vitura's Doctors on Demand / Candor Medical consumer telehealth business model and digital prescribing workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/viturahealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitura Health